CONFERENCE UPDATES: ESMO 2021

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab shows efficacy for early-stage TNBC: KEYNOTE-522 phase 3 trial

Get access to our exclusive articles.